about
Psychostimulants and cognition: a continuum of behavioral and cognitive activationArgatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.Slow clearance of Plasmodium vivax with chloroquine amongst children younger than six months of age in the Brazilian Amazon.Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsThrombolysis in pediatric stroke study.Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years.Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective studyReview of commonly used age-based weight estimates for paediatric drug dosing in relation to the pharmacokinetic properties of resuscitation drugs.Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile.Evaluation of the paediatric dose of chloroquine in the treatment of Plasmodium vivax malaria.Advances in Drug Discovery and Development for Pediatric Tuberculosis.Cocaine self-administration punished by intravenous histamine in adolescent and adult rats.Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsPharmacokinetics in special populations.Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokineticsSystematic Review of the Effects of Asbestos Exposure on the Risk of Cancer between Children and Adults.Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume.The pharmacokinetic evaluation of artemisinin drugs for the treatment of malaria in paediatric populations.Dried blood spots, pharmacokinetic studies and better medicines for children.Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.Neonatal pharmacology: extensive interindividual variability despite limited size.Off-label drug prescribing in a Portuguese paediatric emergency unit.Pediatric drug development: formulation considerations.Theoretical pharmacokinetic drug alterations in pediatric celiac disease.Challenges Associated with Route of Administration in Neonatal Drug Delivery.Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective.Examining Small Intestinal Transit Time as a Function of Age: Is There Evidence to Support Age-Dependent Differences among Children?Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy.How much do we know about drug handling by SLC and ABC drug transporters in children?Sunscreens in human plasma and urine after repeated whole-body topical application.Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy.Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology.Intravenous Thrombolysis at 3.5 Hours From Onset of Pediatric Acute Ischemic Stroke.
P2860
Q22242285-345955E2-3314-420B-823D-72C0343C6AE9Q33368634-BB9B7600-765F-46BA-8795-C6553EF564B2Q33559051-7BE9F315-0CB4-47DA-97E5-A47E50AEA806Q33609231-8E2FCA17-7BDB-4ABD-8923-1F86A576C110Q33826417-F552AD59-855A-4EAA-B621-D42A9EBACBF8Q34142715-A1F2920B-3851-40EC-9547-7C9F8802FAA1Q35055212-73D4ED59-77B9-4FDE-BFE1-C14C346A6049Q35126086-4A1ADE4A-B0EE-48A8-82C2-9E14D90F1829Q35826042-7581436F-7EFA-4CFC-9DBD-2175FCAFCBEBQ36438820-F56DE745-6163-4ACA-A432-ECC98A97B1EEQ36790141-B0B5DE6C-A0AE-4453-992E-1841BC929A64Q36806593-C61E03FE-D699-4C9F-8BC6-CD927AAA1E79Q37106018-FC70BBB9-D63F-4C87-9C19-2D0144820979Q37108173-250C37A8-BA1A-4442-A0C4-32753ED847A9Q37134041-697D6CDF-729B-4132-A218-71719392610DQ37137504-6BF937A6-A4EE-4211-9CDC-16DF0F26F6CFQ37378093-93A91B3C-FEFC-4C54-953F-06A5ACAA6B22Q37550561-B2892D79-7DB2-4A0C-8576-95D648BA2063Q37551700-02A3115C-788F-4899-A270-FFF99D763098Q37581886-E7ACCA97-FD9E-4FF5-BB6E-CADDC307A6C0Q37600374-0E757C6A-2EE4-4ED1-8DE3-7B5FB33EFD1EQ37841602-B3060E60-943A-40EC-8899-78CE64D8BE0CQ37859735-677ADC19-7619-44FF-B2AC-82F757D8E8E4Q37872784-F9875185-5265-4D11-9983-7E2591888EBAQ38000252-0B544C70-7AA1-48FD-9A68-60AEA64582DDQ38051105-68311BD6-C299-42EB-A477-10016542A33FQ38183868-7B8C2D90-0823-4C97-8293-B209A918F141Q38544086-1C99C8FA-42DE-4C8E-934C-1CF58F485DACQ38561363-E2BF788D-9F2A-4EB0-BC12-890BAB9B9C2CQ38951196-91E751AB-C95A-4220-A673-1A88DD9FE704Q39920399-5556B7D4-6525-4539-AA7E-B26B0F174167Q42283823-DFB263B9-B42F-41BE-8DB0-6F657A59C1DDQ42669945-6D9E16AB-2C97-4AF3-A24F-4C21144FD252Q44644877-7469483D-012E-44A5-97CF-BC1D63E03FECQ45938833-8FCD6D1E-F97B-4FD4-929F-4C4A9ED619C3Q46790433-506EEE3A-A0BE-48DE-84A2-58320B515F08Q47318170-DC00E1FD-80D1-45A4-80E1-EA5058714CCDQ47607659-0395B475-595F-4E08-AF2E-A9327736987DQ48607357-FD7A1A81-DAE4-4710-B1BB-71A847035983Q50183352-E084139C-B7BF-4115-A6F6-5BD125A7DD59
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Drug metabolism and disposition in children.
@ast
Drug metabolism and disposition in children.
@en
type
label
Drug metabolism and disposition in children.
@ast
Drug metabolism and disposition in children.
@en
prefLabel
Drug metabolism and disposition in children.
@ast
Drug metabolism and disposition in children.
@en
P2860
P1476
Drug metabolism and disposition in children.
@en
P2093
Strolin Benedetti M
P2860
P304
P356
10.1046/J.1472-8206.2003.00140.X
P577
2003-06-01T00:00:00Z